Analysts Have Spoken & Consensus Is in for Johnson & Johnson (NYSE:JNJ), Seattle Genetics, Inc. (NASDAQ:SGEN)

Johnson & Johnson (NYSE:JNJ) shares have a current ABR (average broker recommendation) of 2.22. This recommendation is offered by Zacks Research. The rating lands on a sliding numerical scale from 1 to 5. A recommendation of 5 would indicate a Strong Sell, and a 1 would signify a Strong Buy. The mean rating may help provide a general sense of analyst sentiment on company shares.

Sell-side analysts taken into consideration by Zacks have also provided price target estimates on shares of Johnson & Johnson (NYSE:JNJ). The highest current target is $140. The lowest price target out of the polled analysts is presently $81. The consensus target price is currently noted at $127.5. Analysts may employ various techniques to help predict future stock price levels.

On the earnings front, Johnson & Johnson (NYSE:JNJ) is expected to post quarterly earnings per share of $1.79. This is the current consensus figure provided by Zacks. Investors and analysts will be looking for the company to next post earnings on or around 2017-07-18. Johnson & Johnson (NYSE:JNJ) most recently reported quarterly EPS of $1.83 for the quarter ending 2017-03-31. The gap between the actual and the projected estimate leading up to earnings created a surprise factor of 3.39%.

According to data provided by Zacks Research, Seattle Genetics, Inc. (NASDAQ:SGEN) has a consensus target price of $60.272 on the stock. Out of the polled analysts providing targets, the high is currently $75, while the low is resting at $43. Analyst price targets may vary depending on the individual method used to calculate the estimate.
Turning to earnings, analysts are expecting Seattle Genetics, Inc. (NASDAQ:SGEN) to post a current quarter EPS of $-0.44. This consensus number is compiled by Zacks Research. For the period ending on 2017-03-31, the company reported EPS for the quarter of $-0.42. The resulting surprise factor from the difference between the reported number and the consensus estimate going into earnings was -2.44%. After a company reports earnings, the stock may see increased activity. The next earnings report date is scheduled on or near 2017-07-25.
In terms of analyst ratings, Seattle Genetics, Inc. (NASDAQ:SGEN) has a current ABR of 2.42. This average broker recommendation is given by Zacks using a scale from 1 to 5. According to this scale, a rating of 1 or 2 would indicate a Buy, and a rating of 4 or 5 would signify a Sell recommendation. A 3 would indicate a Hold on the stock.

Leave a Comment